PROCESSA PHARMACEUTICALS INC (PCSA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.06+0.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PCSA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
PCSA — private placement
Dated 2026-07-29
by reference. Shares of Common Stock held by holders thereof immediately prior to the First Effective Time (as defined in the Merger Agreement) remained outstanding and were unaffected by the Merger. Immediately following the consummation of the Merger but prior to giving effect to the Financing (as defined below), assuming the conversion of shares of Series A Preferred Stock issued pursuant to the Merger Agreement into shares of Common Stock (without giving effect to any beneficial ownership…
Why it matters: This data will show if VT-7208 can treat CSU well. This affects its market chance.
Supportive ifTop-line data from the Phase 2 proof-of-concept study in CSU is released in the first half of 2028.
Worry ifThe study does not show real improvements in CSU symptoms.
Why it matters: New or improved partnerships could provide funding and resources. Weak agreements may limit growth.
Watch forAnnouncement of a new licensing deal or partnership.
Also watch forNews of a partnership being terminated or not renewed.
Why it matters: Advancing clinical trials is key for future partnerships and growth. Delays could hurt investor confidence.
Supportive ifA trial phase is successful. Or, regulatory approval is announced.
Worry ifNo news on clinical trials or more delays are announced.
Why it matters: Data from this trial could prove VT-7208 works for RMS. This affects its future plans.
Supportive ifTop-line data from the Phase 2 proof-of-concept study in RMS is released in the second half of 2028.
Worry ifThe study results show no real benefits for RMS patients when compared to current therapies.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$325 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $1,305 loss on $10,000 · 13.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,455 loss on $10,000 · 84.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: High cash burn could impact funding for clinical trials and operations, raising concerns.
Worry ifOperating cash burn remains below $2 million per quarter.
Less concerning ifOperating cash burn exceeds $3 million per quarter.
Why it matters: This study shows progress in developing VT-7208 for multiple sclerosis. It shows a commitment to growing the pipeline.
Supportive ifThe Phase 2 study for RMS is initiated in the first half of 2027.
Worry ifThe initiation of the RMS study is delayed or canceled.
Why it matters: Good data would show that VT-7208 works. It would also support buying Vidya.
Supportive ifData from the Phase 2 study in food allergy shows big gains over placebo.
Worry ifData from the Phase 2 study in food allergy shows no big gains over placebo.
Why it matters: Closing this financing is key. It will fund clinical trials and operations until 2029.
Supportive ifThe private placement closes on July 30, 2026. Funds have been received.
Worry ifThe private placement fails to close or is significantly delayed.
Why it matters: Updates on these studies will indicate the progress of VT-7208 and its market potential.
Watch forUpdates show good interim results from the Phase 2 studies in CSU or RMS.
Also watch forUpdates indicate setbacks or negative results from the Phase 2 studies in CSU or RMS.
Why it matters: Approval is needed for Series A preferred stock to change into common stock. This affects ownership.
Watch forStockholders approve changing Series A preferred stock to common stock.
Also watch forStockholders reject changing Series A preferred stock to common stock.